Skip to main content

Table 1 Patients without evidence of CNS abnormalities

From: Mudd’s disease (MAT I/III deficiency): a survey of data for MAT1A homozygotes and compound heterozygotes

Patient

Sex

Age at last report years

MAT1A allele 1/allele 2

MAT activity % of WT

Cause ascer- tain Met

Age < 5 m Met range

Age ≥ 5 m Met mean ± SD

MRI (age)

Citation

G1

F

40.4

c.966T>G (p.Ile322Met)

7.8*

NBS

1270

373 ± 133

Normal (22)

[17, 25, 46, 58]

c.966T>G (p.Ile322Met)

21/21

G2

M

38

c.914T>C (p.Leu305Pro)

10.2*

NBS

364–583

394 ± 118

---

[17, 25]

c.966T>G (p.Ile322Met)

26/21

G3

F

2

c.164C>A (p.Arg55Asp)

10.91*

NBS

389–1020

315

---

[17, 25]

c.1070C>T (p.Pro357Leu)

26/31

G4

F

31.4

c.1068G>A (p.Arg356Gln)

17.5*

NBS

42–408

146 ± 38

---

[17, 26]

c.1132G>A (p.Gly378Ser)

11/0.2

402

2

M

60.1

c.539insTG (p.Thr185X)

28*

Breath odor

---

805 ± 106

Normal (31)

[19, 20, 78]

c.539insTG (p.Thr185X)

3

F

21.5

c.539insTG (p.Thr185X)

NA

NBS

1870–2542

777 ± 169

Normal (6)

[26, 58]

c.539insTG (p.Thr185X)

1870

10a

M

25

c.595C>T (p.Arg199Cys)

11/11

NBS

496–670

520 ± 124

---

[26, 58]

c.595C>T (p.Arg199Cys)

670

11a

F

28.5

c.595C>T (p.Arg199Cys)

11/11

NBS

591–654

475 ± 118

---

[26, 58]

c.595C>T (p.Arg199Cys)

591

14

F

6.4

c.966T>G (p.Ile322Met)

11/11

NBS

440–467

225 ± 57

---

[27, 58]

c.1031A>C (p.Glu344Ala)

15b

F

2.2

c.1132G>A (p.Gly378Ser)

0.2/75

NBS

383–1089

519

---

[80]

c.1161G>A (p.Trp387X)

16b

F

4.7

c.1132G>A (p.Gly378Ser)

0.2/75

Family

---

782 ± 400

---

[80]

c.1161G>A (p.Trp387X)

17

F

21.4

c.791C>T (p.Arg264Cys)

0.3/31

NBS

648

322

---

[42]

c.1070C>T (p.Pro357Leu)

18

M

21.2

c.1070C>T (p.Pro357Leu)

31/31

NBS

505

325 ± 244

---

[42]

c.1070C>T (p.Pro357Leu)

19

F

16.5

c.1067G>C (p.Arg356Pro)

11/31

NBS

622

175

---

[34, 42]

c.1070C>T (p.Pro357Leu)

21

F

7.1

c.836G>T (p.Gly279Val)

NA/2

NBS

596

436 ± 1

---

[34]

c.964A>G (p.Ile322Val)

23

F

3.9

c.539insTG (p.Thr185X)

NA

NBS

216–1457

665 ± 160

---

[38]

c.822G>C (p.Trp274Ser)

24c

M

1.2

c.689T>G (p.Val230Gly)

NA

NBS

518–525

769 ± 112

---

 

c.689T>G (p.Val230Gly)

25c

F

4.9

c.689T>G (p.Val230Gly)

NA

Family

838 ± 18

---

 

c.689T>G (p.Val230Gly)

26

F

2.9

c.527T>A (p.Leu176Gln)

NA

NBS 57

57–200

76 ± 24

---

 

c.527T>A (p.Leu176Gln)

28

F

20

c.65C>T (p.Ser22Leu)

46/46

NBS

---

975 ± 177

normal (20)

[34, 37, 44]

c.65C>T (p.Ser22Leu)

33

U

2

c.856G>A (p.Asp286Asn)

NA

NBS

106–1570

   

del at least exons 6-8

40

F

0.4

c.1141G>A (p.Gly381Arg)

25/25

NBS

1207–2121

1673

---

[34]

c.1141G>A (p.Gly381Arg)

44

M

0.2

c.529C>T (p.Arg177Trp)

NA

NBS 97

97–641

---

---

 

c.529C>T (p.Arg177Trp)

48

M

5.4

c.446T>A (p.Met64Lys)

NA

NBS 134

134–1567

---

Normal (yearly, final at 5) DQ 88

[39]

c.589delC (p.Pro197Leufs*26)

49

F

0.3

c.110T>C (p.Ile37Thr)

NA

NBS 407

403–408

---

---

[31]

c.271G>A (p.Gly91Ser)

52

M

0.54

c.823G>C (p.Gly275Arg)

NA

NBS

949–1074

---

normal (0.5)

 

c.823G>C (p.Gly275Arg)

53

F

2.3

c.862A>G (p.Thr288Ala)

NA

NBS

121–484

495 ± 275

 

[30]

c.862A>G (p.Thr288Ala)

54

F

2.0

c.1064T>G (p.Leu355Arg)

NA

NBS 185

185–410

---

---

[30]

c.1064T>G (p.Leu355Arg)

57

U

3.5

c.169+1G>A

NA

NBS 860

860–1130

918 ± 84

---

 

c.169+1G>A

58d

M

12.3

not sequenced

22.7*

NBS

268–1005

369 ± 237

---

[15]

268

59d

M

13.7

not sequenced

23.1*

Family

---

350 ± 50

---

[15]

64

M

4.5 m

c.596G>A (p.Arg199His)

NA

NBS

118–208

---

---

 

c.596G>A (p.Arg199His)

  1. Patients are assigned the same identifiers as were used when they were first described in the following papers: Patients G1, G2, G3, G4 [17]; Patients 3, 10, 11 [58]; Patients 17, 18, 19; numbers 1, 2 and 5 [42]; Patient 28: patient 1 [44]; Patients 53, 54: patients 14 and 18 [30]
  2. *Activity based on assay of hepatic extract; others based on activity of mutant recombinant forms expressed in E coli [34]
  3. aSibs are designated by the same superscript
  4. Cont. indicates that methionine restriction or AdoMet supplementation was continuing at last report
  5. NBS: Newborn screening
  6. NA: not available
  7. Met: methionine concentration in umol/L